Open Access Open Access  Restricted Access Subscription or Fee Access

Psoriasis: Latest Trends in Treatment, Diagnosis and Management in Medical Science

Amit Kumar Dutta, Ritu Kumari

Abstract


Psoriasis is a common chronic inflammatory and autoimmune skin disease that primarily affects the skin. It affects about 2–4% of the world populations. It is clinically characterized by skin rashes, highly inflamed red scale itchy plaque. Abundant therapeutic agents are accessible for the treatment of psoriasis. Wide range of therapeutic mediators such as coal tar, topical corticosteroids, anthralin, retinoid, calcineurin inhibitors, methotrexate, cyclosporine are proven to be effective in treating mild to severe psoriasis. Psoriasis is a lifelong disease and the management, diagnosis and treatment of psoriasis depends on the severity of the disease. Topical therapy is first line treatment of psoriasis management as it has many advantages. For severe conditions, systemic treatment and phototherapy is indicated.


Keywords


Psoriasis, common types, epidemiology, causes, factors, latest treatment

Full Text:

PDF

References


Sala M, Elaissari A, Fessi H. Advances in Psoriasis Physiopathology and Treatments: Up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS). J Controlled Release. 2016; 239: 182–202p.

Liu Y, Krueger JG, Bowcock AM. Psoriasis: genetic associations and immune system changes. Genes and Immunity. 2007; 8(1): 1–2p.

Bailey EE, Ference EH, A. Alikhan A, et al. Combination treatments for Psoriasis: A systematic review and meta-analysis. Arch Dermatol. 2012; 148: 511–522p.

Lee S, Coleman CI, Limone B, et al. Biologic and non-biologic systemic agents and phototherapy for treatment of chronic plaque psoriasis. Med J Aust. 2006; 185(10): 562– 564p.

Henley ND. Rapid-onset skin rash- Guttate psoriasis. American Family Physician. 2012; 86: 361–362p.

Syed ZU, Khachemoune A. Inverse psoriasis: Case presentation and review. American Journal of Clinical Dermatology. 2011; 12: 143–146p.

Viguier M, Aubin F, Delaporte E, et al. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis. Archives of Dermatology. 2012; 148(12): 1423–1425p.

Hawilo A, Zaraa I, Benmously R, et al. Erythrodermic Psoriasis: Epidemiological clinical and therapeutic features about 60 cases. La tunisie Medicale. 2011; 89(11): 841–847p.

Aydin SZ, Castillo-Gallego C, Ash ZR, et al. Ultrasonographic assessment of nail in psoriatic disease shows a link between onychopathy and distal interphalangeal joint extensor tendon enthesopathy. Dermatology. 2012; 225(3): 231–235p.

Parisi R, Symmons DP, Griffiths CE, et al. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. Journal of Investigative Dermatology. 2013; 133: 377–385p.

Nickoloff BJ. Skin Innate Immune System in Psoriasis: Friend or Foe. Journal of Clinical Investigation. 1999; 104: 1161–1171p.

Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. New England Journal of Medicine. 1999; 341(24): 1817–1828p.

Krueger G, Ellis CN. Psoriasis—recent advances in understanding its pathogenesis and treatment. Journal of the American Academy of Dermatology. 2005; 53(1): 94–100p.

Mudigonda P, Mudigonda T, Feneran AN, et al. Interleukin-23 and Interleukin-17: Importance in Pathogenesis and Therapy of Psoriasis. Dermatology Online Journal. 2012; 18(10): 1p.

Mease PJ, Armstrong AW. Managing patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of psoriatic Arthritis in patients with psoriasis. Drugs. 2014; 74: 423–441p.

Bhutani T, Koo J, Maibach HI. Efficacy of clobetasol spray: factors beyond patient compliance. Journal of Dermatological Treatment. 2012; 23(1): 11– 15p.

Nast A, Kopp IB, Augustin M, et al. Evidence based (s3) guidelines for the treatment of psoriasis vulgaris. Journal der deutschen dermatologischen Gesellschaft. 2007; 5(s3): 1–19p.

Greaves MW, Weinstein GD. Treatment of Psoriasis. New England Journal of Medicine. 1995; 332(9): 581–589p.

Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: A Review. Altern Med Rev. 2005; 10(2): 94–111p.

Oostveen AM, Beulens CA, Kerkhof PC, et al. The effectiveness and safety of short‐contact dithranol therapy in Paediatric Psoriasis: A prospective comparison of regular day care and day care with telemedicine. British Journal of Dermatology. 2014; 170(2): 454–730p.

Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: Vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. Journal of the American Academy of Dermatology. 1997; 37(1): 85–92p.

Martin EG, Sanchez RM, Herrera AE, et al. Topical tacrolimus for the treatment of Psoriasis on the Face, Genitalia, Intertriginous Areas and Corporal Plaques. Journal of Drugs in Dermatology: JDD. 2006; 5(4): 334–336p.

Huber C, Christophers E. Kerotolytic effect of salicylic acid. Archives of Dermatological Research. 1977; 257(3): 293–297p.

Cordoro KM. Systemic and light therapies for the management of Childhood Psoriasis: part II. Skin Therapy Lett. 2008; 13(4): 1–3p.

Holme SA, Anstey AV. Phototherapy and PUVA Photochemotherapy in Children. Photodermatol Photoimmunol Photomed. 2004; 20(2): 69–75p.

Lara CI, Ramnarine S, Lansang P. Treatment of childhood psoriasis with Phototherapy and Photochemotherapy. Clin Med Insights Pediatr. 2013; 7: 25–33p.

Pasic A, Ceovi R, Lipogenic J, et al. Phototherapy in Pediatric Patients. Pediatr Dermatol. 2003; 20(1): 71–77p.

Kopp T, Karlhofer F, Szépfalusi Z, Schneeberger A, Stingl G, Tanew A. Successful use of acitretin in conjunction with narrowband ultraviolet B phototherapy in a child with severe pustular psoriasis, von Zumbusch type. Br J Dermatol. 2004; 151(4): 912–916p.

Cordoro KM. Systemic and light therapies for the management of Childhood Psoriasis: part II. Skin Therapy Lett. 2008; 13(4): 1–3p.

Brecher AR, Orlow SJ. Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol. 2003; 49(2): 171–182p.

Geel van MJ, Mul K, Jager de ME, et al. Systemic treatments in Paediatric Psoriasis: A Systematic Evidence- based Update. J Eur Acad Dermatol Venereol: JEADV. 2015; 29(3): 425–437p.

Kalb RE, Strober B, Weinstein G, et al. Methotrexate and Psoriasis: 2009. J Am Acad Dermatol. 2009; 60(5): 824–837p.

Wright NA, Piggott CD, Eichenfield LF. The role of biologics and other systemic agents in the treatment of pediatric psoriasis. Semin Cutan Med Surg. 2010; 29(1): 20–27p.

Hashkes PJ, Becker ML, Cabral DA, et al. Methotrexate: New uses for an old drug. J Paediatric. 2014; 164(2): 231–236p.

Kilic SS, Hacimustafaoglu M, Celebi S, et al. Low dose cyclosporin A treatment in generalized pustular psoriasis. Pediatr Dermatol. 2001; 18(3): 246–248p.

Mahe E, Bodemer C, Pruszkowski A, et al. Cyclosporine in Childhood Psoriasis. Arch Dermatol. 2001; 137(11): 1532–1533p.

Ellis CN. Safety issues with cyclosporine. Int J Dermatology. 1997; 36(Suppl 1): 7–10p.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Research & Reviews: A Journal of Biotechnology